A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
NCT ID: NCT06869551
Last Updated: 2026-01-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
60 participants
INTERVENTIONAL
2025-03-13
2031-03-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
NCT06979453
A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants With Moderate to Severe Plaque Psoriasis
NCT04772079
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment
NCT04908189
An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age
NCT02698475
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
NCT04908202
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A
Deucravacitinib
Specified dose on specified days
Arm B
Deucravacitinib
Specified dose on specified days
Placebo
Specified dose on specified days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Deucravacitinib
Specified dose on specified days
Placebo
Specified dose on specified days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants must have at least three joints that are affected by arthritis.
* Participants must have tried at least one type of medicine for JPsA for at least three months, but it didn't work well or caused problems.
Exclusion Criteria
* Participants must not have other types of Juvenile Idiopathic Arthritis (JIA) that aren't JPsA,
* Participants must not have a history of chronic eye inflammation (uveitis), or were diagnosed with uveitis within the last three months.
5 Years
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution - 0038
Lancaster, California, United States
Local Institution - 0020
Chicago, Illinois, United States
Local Institution - 0023
Indianapolis, Indiana, United States
Local Institution - 0059
North New Hyde Park, New York, United States
Local Institution - 0065
Cincinnati, Ohio, United States
Local Institution - 0066
Cleveland, Ohio, United States
Local Institution - 0036
Austin, Texas, United States
Local Institution - 0068
Fortaleza, Ceará, Brazil
Local Institution - 0032
Cuiabá, Mato Grosso, Brazil
Local Institution - 0030
Belo Horizonte, Minas Gerais, Brazil
Local Institution - 0013
Curitiba, Paraná, Brazil
Local Institution - 0072
Curitiba, Paraná, Brazil
Local Institution - 0007
Recife, Pernambuco, Brazil
Local Institution - 0033
Porto Alegre, Rio Grande do Sul, Brazil
Local Institution - 0008
Porto Alegre, Rio Grande do Sul, Brazil
Local Institution - 0069
Xangri-lá, Rio Grande do Sul, Brazil
Local Institution - 0073
Vila Clementino, São Paulo-SP, Brazil
Local Institution - 0027
Rio de Janeiro, , Brazil
Local Institution - 0047
São Paulo, , Brazil
Local Institution - 0010
São Paulo, , Brazil
University Multiprofile Hospital for Active Treatment "Sveti Georgi" EAD
Plovdiv, , Bulgaria
Local Institution - 0062
Sofia, , Bulgaria
Local Institution - 0049
Beijing, Beijing Municipality, China
The Children's Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Local Institution - 0060
Guangzhou, Guangdong, China
Childrens Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
The First Hospital of Jilin University
Changchun, Jilin, China
The Children's Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Children's Hospital of Fudan University
Shanghai, , China
Fakultni nemocnice Olomouc
Olomouc, Olomoucký kraj, Czechia
Fakultni nemocnice v Motole
Prague, Praha 5, Czechia
Kinderklinik des Uni-Klinikums Erlangen
Erlangen, , Germany
Praxis Kinder- und Jugendrheumatologie Dr. Ivan Foeldvari
Hamburg, , Germany
University of Naples Federico II
Napoli, Campania, Italy
Azienda Ospedaliera Universitaria Meyer IRCCS
Florence, Tuscany, Italy
Local Institution - 0017
San Juan, , Puerto Rico
Spitalul Clinic de Urgenta pentru Copii Cluj-Napoca
Cluj-Napoca, Cluj, Romania
Local Institution - 0048
Iași, Iaşi, Romania
Sc Medaudio-Optica Srl
Râmnicu Vâlcea, Vâlcea County, Romania
Hospital Universitari Vall d'Hebron
Barcelona, Barcelona [Barcelona], Spain
Hospital Universitario Ramón y Cajal
Madrid, Madrid, Comunidad de, Spain
Hospital Universitari i Politecnic La Fe
Valencia, , Spain
Istanbul Universitesi Cerrahpasa
Istanbul- Fatih, Istanbul, Turkey (Türkiye)
Local Institution - 0061
Ankara, , Turkey (Türkiye)
Local Institution - 0044
Ankara, , Turkey (Türkiye)
Umraniye Training and Research Hospital
Istanbul, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Role: CONTACT
First line of the email MUST contain the NCT# and Site#
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Site 0038
Role: primary
Site 0020
Role: primary
Site 0023
Role: primary
Site 0059
Role: primary
Site 0065
Role: primary
Site 0066
Role: primary
Site 0036
Role: primary
Site 0068
Role: primary
Site 0030
Role: primary
Site 0013
Role: primary
Site 0072
Role: primary
Site 0007
Role: primary
Site 0008
Role: primary
Site 0069
Role: primary
Site 0073
Role: primary
Site 0027
Role: primary
Site 0047
Role: primary
Krastina Stefanova-Kelly, Site 0054
Role: primary
Site 0062
Role: primary
Site 0049
Role: primary
Xuemei Tang, Site 0056
Role: primary
Site 0060
Role: primary
Haiguo Yu, Site 0052
Role: primary
sirui yang, Site 0053
Role: primary
Meiping Lu, Site 0051
Role: primary
Li Sun, Site 0050
Role: primary
Katerina Bouchalova, Site 0003
Role: primary
Rudolf Horvath, Site 0002
Role: primary
Tobias Krickau, Site 0063
Role: primary
Ivan Foeldvari, Site 0026
Role: primary
Roberta Naddei, Site 0005
Role: primary
Gabriele Simonini, Site 0004
Role: primary
Site 0017
Role: primary
Mihaela Sparchez, Site 0067
Role: primary
RAZVAN IONITESCU, Site 0040
Role: primary
Mireia Corbeto, Site 0046
Role: primary
Alina Lucica Boteanu, Site 0041
Role: primary
LUCIA LACRUZ PEREZ, Site 0042
Role: primary
Ozgur Kasapcopur, Site 0043
Role: primary
Site 0061
Role: primary
Site 0044
Role: primary
Betul Sozeri, Site 0045
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
BMS Clinical Trial Patient Recruiting
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IM011-1071
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.